【财经分析】推动经济回升向好 这些调控政策值得期待

Group 1 - The core viewpoint is that 2026 will mark the beginning of a new growth phase for China's economy, with various measures aimed at boosting consumption, stabilizing investment, and fostering new growth drivers [1] Group 2 - Consumption is identified as the main engine of economic growth, with final consumption expenditure contributing 53.5% to economic growth in the first three quarters of 2025, an increase of 9.0 percentage points compared to 2024 [2] - The optimization of the old-for-new policy for consumer goods will be a key measure to stimulate consumption in 2026, including subsidies for vehicle scrappage and replacement, as well as for home appliances and digital products [2][3] Group 3 - The potential for service consumption in China is significant, and promoting service consumption will be a focus in 2026, with recommendations to relax entry restrictions and attract more social capital [4] - There is a need to enhance public service spending to improve residents' consumption capacity, emphasizing investment in education, healthcare, and other public services [3] Group 4 - The implementation of policies to stimulate private investment is crucial for 2026, with expectations for new growth points in various sectors, including traditional industry upgrades and infrastructure [6] - The "Two New" and "Two Heavy" projects will be optimized to support major national strategies and enhance government investment's guiding role [6] Group 5 - The establishment of a unified national market construction regulation is essential to address "involution" in competition, ensuring fair and orderly market conditions [7] - The regulation aims to eliminate local protectionism and improve cash flow for enterprises, particularly small and medium-sized ones [7] Group 6 - The "Artificial Intelligence +" initiative will be deepened in 2026, expanding its application across various sectors, including education and healthcare, to drive economic transformation [9] - The development of innovative pharmaceuticals is highlighted, with over 110 domestic innovative drugs approved since the 14th Five-Year Plan, and a market size of 1000 billion [9]